NCT03840343View on ClinicalTrials.gov

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 23, 2019

Primary Completion Date

August 4, 2020

Study Completion Date

August 4, 2020

Conditions
Diabetic Kidney DiseaseDiabetic NephropathiesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Chronic Kidney DiseaseDiabetic Nephropathy Type 2Kidney FailureKidney Insufficiency
Interventions
BIOLOGICAL

Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose

Two MSC infusions of 2.5x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery

BIOLOGICAL

Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose

Two MSC infusions of 5.0x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Regenerative Medicine Minnesota

UNKNOWN

lead

Mayo Clinic

OTHER

NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease | Biotech Hunter | Biotech Hunter